Contrasting Madrigal Pharmaceuticals (NASDAQ:MDGL) & PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics (NASDAQ:PTCT) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Profitability

This table compares PTC Therapeutics and Madrigal Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	N/A	-1.32%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Analyst Recommendations

This is a summary of current ratings and target prices for PTC Therapeutics and Madrigal Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2	3	10	1	2.62
Madrigal Pharmaceuticals	1	2	15	0	2.78

PTC Therapeutics presently has a consensus target price of $94.93, suggesting a potential upside of 50.67%. Madrigal Pharmaceuticals has a consensus target price of $699.20, suggesting a potential upside of 52.90%. Given Madrigal Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than PTC Therapeutics.

Earnings & Valuation

This table compares PTC Therapeutics and Madrigal Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.01 billion	5.21	$682.64 million	($0.58)	-108.63
Madrigal Pharmaceuticals	$958.40 million	11.02	-$288.28 million	($12.89)	-35.48

PTC Therapeutics has higher revenue and earnings than Madrigal Pharmaceuticals. PTC Therapeutics is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

PTC Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.04, meaning that its share price is 204% less volatile than the S&P 500.

Insider and Institutional Ownership

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 5.3% of PTC Therapeutics shares are owned by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

PTC Therapeutics beats Madrigal Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About PTC Therapeutics

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.